Sydney Jennings

In a phase 2 trial in China, UBT251 led to up to 19.7% mean weight loss at 24 weeks vs 2.0% with placebo in adults with overweight or obesity.

In the REDEFINE 4 trial, CagriSema led to 23% weight loss at 84 weeks but did not demonstrate noninferiority to tirzepatide 15 mg in adults with obesity.

In 142 000 adults, adding Galleri to standard screening reduced stage IV diagnoses over time in a prespecified group of 12 cancers, according to new data.

SMART trial finds clesrovimab protects high-risk children in a second RSV season, with consistent safety and fewer RSV-related hospitalizations.

Real-world data show GSK’s Arexvy is linked to 75.6% lower hospitalization risk in adults ≥60, with reduced CV events and COPD exacerbations.

Data show 44-week durable clinical remission in ulcerative colitis and endoscopic response in Crohn disease with duvakitug, a TL1A-targeting monoclonal antibody now in phase 3 trials.

New phase 3 data show single-inhaler triple therapy boosts FEV₁ and cuts severe asthma attacks for patients uncontrolled on ICS–LABA.

FDA updates menopause hormone therapy labels, dropping boxed warning claims on heart disease, breast cancer, and dementia after evidence review.

Calling physicians “providers” undermines ethics and professionalism, an American College of Physicians position paper argues.

Adults with obesity achieved up to 12.1% mean weight loss with oral ribupatide vs placebo in a 26-week phase 2 trial.

Booster-backed speed-of-processing brain training links to lower Alzheimer disease and dementia diagnoses, suggesting modest computer exercises may delay decline.

Three-year BE HEARD data show bimekizumab sustains HS lesion clearance, cuts draining tunnels, and improves severity and quality of life.

FDA insulin updates, new obesity drug data, vaccine hesitancy strategies, and depression screening insights are featured in this week’s episode.

FDA clears a dissolvable sildenafil oral film for erectile dysfunction, offering discreet, water-free dosing and strong phase 3 results ahead of 2026 launch.

Researchers found that 58% of infants with atopic dermatitis achieved a 75% improvement in EASI-75 at week 4 with once-daily roflumilast cream 0.05%.

A new study reveals icotrokinra's comparable efficacy to existing therapies, offering hope for treatment-refractory patients facing resistance challenges.

The FDA delays approval of Anaphylm, a sublingual epinephrine film for anaphylaxis, citing administration and human factors study deficiencies.

GRAIL advances cancer detection with FDA application for Galleri, a groundbreaking blood test aimed at early detection of multiple cancers.

Roche's CT-388 shows promising results with 22.5% weight loss in a phase 2 trial, advancing obesity treatment options significantly.

Centanafadine's FDA priority review signals potential innovation in ADHD treatment, offering a new nonstimulant option for diverse patient needs.

Colorectal cancer emerges as the top cancer killer for US adults under 50, highlighting urgent needs for early detection and screening strategies.

The FDA updates Afrezza's prescribing information, enhancing dosing guidance for adults switching from injected insulin to improve glycemic control.

ACON Laboratories launches the first FDA-cleared at-home test for RSV, influenza, and COVID-19, enhancing respiratory symptom management for families.

National health trends for 2025 show a complex mix of improved cancer screenings alongside rising chronic conditions and affordability gaps.

Results show significant concerns about topical steroid use in chronic skin diseases, highlighting the need for proactive long-term management strategies.

Sebela Pharmaceuticals seeks FDA approval for tegoprazan, a new treatment for GERD, targeting heartburn, erosive esophagitis, and maintenance healing.

A study reveals that using population-based eGFR percentiles can enhance early detection of chronic kidney disease and improve patient outcomes.

Your daily dose of the clinical news you may have missed.

This episode reviews intranasal epinephrine use, pediatric atopic dermatitis data, dementia screening tools, adolescent TMS, and oral PCSK9 therapy.

New phase 3 data reveals lumateperone significantly boosts remission rates in adults with major depressive disorder, offering hope for lasting relief.